CarlosEnriqueVigil GonzalesMDFACP

PubMed

• 3 citations
  A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
  Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J. Lee, Karen W.L. Yee, Andrew Dalovisio, Eunice S. Wang, Jua...> ;Blood Cancer Journal. 2021 Oct 30
• 12 citations
  Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
  Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel J Cook, Philippe Rousselot, David A Rizzieri, Jane L Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Jose...> ;Blood Advances. 2023 May 9
• 26 citations
  The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
  Amanda McBride, Sarah Houtmann, Lindsay Wilde, Carlos E. Vigil, Christine M. Eischen, Margaret Kasner, Neil Palmisiano> ;Frontiers in Oncology. 2019 Mar 27
• 1 citations
  Acute Myeloid Sarcoma: An Unusual Cause of Diarrhea.
  Danish Safi, Luna Acharya, Maimoona Khan, Oana Paun, Carlos E. Vigil> ;Cureus. 2020 Oct 1
• 45 citations
  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment
  Alejandro A. Gru, B. H. Haverkos, Aharon G. Freud, Justin Hastings, Nicholas B. Nowacki, Carlos Barrionuevo, Carlos E. Vigil, Rosemary Rochford, Yasodha Natkunam, Robe...> ;Current Hematologic Malignancy Reports. 2015 Oct 8
• 23 citations
  Clinical use of FLT3 inhibitors in acute myeloid leukemia.
  Grerk Sutamtewagul, Carlos E. Vigil> ;Oncotargets and Therapy. 2018 Oct 16
• A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.
  Griffiths, E. A.,Brady, W. E.,Tan, W.,Vigil, C. E.,Thompson, J. E.,Ford, L. A.,Dickey, N. M.,L Bashaw, H.,Sperrazza, J.,Wetzler, M.,Wang, E. S.> ;Leuk. Res.. 2016 Mar 05
• Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥ 60 years old.
  Gupta, N.,Miller, A.,Gandhi, S.,Ford, L. A.,Vigil, C. E.,Griffiths, E. A.,Thompson, J. E.,Wetzler, M.,Wang, E. S.> ;Am. J. Hematol.. 2015 Mar 27
• Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.
  Vigil, C. E.,Tan, W.,Deeb, G.,Sait, S. N.,Block, A. W.,Starostik, P.,Griffiths, E. A.,Thompson, J. E.,Greene, J. D.,Ford, L. A.,Wang, E. S.,Wetzler, M.> ;Leuk. Res.. 2013 Aug 15
• Myelodysplastic syndromes and autoimmune diseases-Case series and review of literature.
  Ustwani, O. A.,Ford, L. A.,Sait, S. J.,Block, A. M.,Barcos, M.,Vigil, C. E.,Griffiths, E. A.,Thompson, J. E.,Wang, E. S.,Ambrus, J.,Wetzler, M.> ;Leuk. Res.. 2013 Aug
• The role of minimal residual disease (MRD) by flow cytometry (FC) in predicting outcome in similarly treated acute lymphoblastic leukemia (ALL) patients.
  Lee HJ, Wright KM, Kandeel E, Tan W, Wilding GE, Ford LA, Sait SN, Block AMW, Barcos MP, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M> ;J. Clin. Oncol.. 2011-05-20
• Comparison of outcome in erythroleukemia patients treated with standard chemotherapy regimens or hypomethylating agents.
  Vigil CE, Tan W, Wilding GE, Garcia-Manero G, Wang ES, Wetzler M, List AF> ;J. Clin. Oncol.. 2011-05-20
• Prognostic value of the ratio of positive axillary lymph node after neoadjuvant chemotherapy in Peruvian patients with breast cancer.
  Vidaurre T, Calderón M, Mantilla R, Vigil CE, León M, Más L, Montanez M, Neciosup SP, Gomez H> ;J. Clin. Oncol.. 2011-05-20
• Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis.
  Vigil CE, Ayala E, Sokol L> ;J. Clin. Oncol.. 2009-05-20
• Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas.
  Vigil CE, Chiappori AA, Williams CA, Shrager HH, Murray BL, Letson DG, Sullivan DM, Garrett CR, D'Amato GZ, Agresta SV> ;J. Clin. Oncol.. 2008-05-20
• Effect of dose intensity and overexpression of topoisomerase iia on survival in patients with locally advanced breast cancer treated with anthracyclines.
  Vidaurre T, Olivera M, Gómez H, Pinto J, Doimi F, Velarde R, Abugattas J, Leon J, Mas L, Vigil C> ;J. Clin. Oncol.. 2008-05-20
• Current progress in targeted therapy for colorectal cancer.
  Ortega, J., Vigil, C. E., Chodkiewicz, C.> ;Cancer Control. 2010 Jan
• Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
  Gómez, H. L., Pinto, J. A., Olivera, M., Vidaurre, T., Doimi, F. D., Vigil, C. E., Velarde, R. G., Abugattas, J. E., Alarcón, E., Vallejos, C. S.> ;Breast. 2011 Feb
• Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database.
  Vallejos, C. S., Gómez, H. L., Cruz, W. R., Pinto, J. A., Dyer, R. R., Velarde, R., Suazo, J. F., Neciosup, S. P., León, M., de la Cruz, M. A., Vigil, C. E.> ;Clin Breast Cancer. 2010 Aug 1
• Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients.
  Gómez, H. L., Castañeda, C. A., Vigil, C. E., Vidaurre, T., Velarde, R. G., Cruz, W. R., Pinto, J. A., Suazo, J. F., Garcés, M. R., Neciosup, S. P., Vallejos, C. S.> ;Hematol Oncol Stem Cell Ther. 2010
• 23 citations
  Safety and efficacy of azacitidine in myelodysplastic syndromes
  Carlos E. Vigil, Taida Martin-Santos, Guillermo Garcia-Manero> ;Drug Design, Development and Therapy. 2010 Sep 9
• Interpretation of cytogenetic and molecular results in patients treated for CML.
  Vigil, C. E., Griffiths, E. A., Wang, E. S., Wetzler, M.> ;Blood Rev. 2011 May
• 5 citations
  Dasatinib-Responsive Mast Cell Neoplasms As Initial Presentation of Chronic Myelogenous Leukemia in Blast Phase
  Carlos E. Vigil, Sa A. Wang, Jorge E. Cortes, Carlos E. Bueso-Ramos, Srdan Verstovsek, Roman Shinder, Su S. Chen, Ruth L. Katz, Abha Khanna, Bita Esmaeli, John T. Mann...> ;Journal of Clinical Oncology. 2011 Jun 10
• Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
  Naqvi, K., Garcia-Manero, G., Sardesai, S., Oh, J., Vigil, C. E., Pierce, S., Lei, X., Shan, J., Kantarjian, H. M., Suarez-Almazor, M. E.> ;J Clin Oncol. 2011 Jun 1
• The significance of quantifiable residual normal karyotype hematopoietic cells for toxicity and outcome.
  Vigil, C., Block, A. W., Wetzler, M.> ;Leuk Lymphoma. 2011 Jun
• Join now to see all

Lectures

• Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018